Neuroprotection in Acute Ischemic Stroke: A Battle Against the Biology of Nature

被引：42

作者：

Ghozy, Sherief ^{[1
,2
]}

Reda, Abdullah ^{[3
]}

Varney, Joseph ^{[4
]}

Elhawary, Ahmed Sallam ^{[5
]}

Shah, Jaffer ^{[6
]}

Murry, Kimberly ^{[7
]}

Sobeeh, Mohamed Gomaa ^{[8
,9
]}

Nayak, Sandeep S. ^{[10
]}

Azzam, Ahmed Y. ^{[11
]}

Brinjikji, Waleed ^{[12
]}

Kadirvel, Ramanathan ^{[1
]}

Kallmes, David F. ^{[1
]}

机构：

[1] Mayo Clin, Dept Neuroradiol, Rochester, MN USA

[2] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford, Oxon, England

[3] Al Azhar Univ, Fac Med, Cairo, Egypt

[4] Amer Univ Caribbean, Sch Med, Philipsburg, Sint Maarten

[5] South Valley Univ, Qena Fac Med, Qena, Egypt

[6] Kateb Univ, Med Res Ctr, Kabul, Afghanistan

[7] Barry Univ, Miami, FL USA

[8] Sinai Univ, Fac Phys Therapy, Cairo, Egypt

[9] Cairo Univ, Fac Phys Therapy, Giza, Egypt

[10] NYC Hlth Hosp Metropolitan, Dept Internal Med, EBHC Program, New York, NY USA

[11] October 6 Univ, Fac Med, Giza, Egypt

[12] Mayo Clin Rochester, Dept Neurosurg, Rochester, MN USA

来源：

FRONTIERS IN NEUROLOGY | 2022年 / 13卷

关键词：

acute ischemic stroke; neuroprotection; ischemia; therapy; management; TISSUE-PLASMINOGEN-ACTIVATOR; TRANSDERMAL GLYCERYL TRINITRATE; HEALTH-CARE PROFESSIONALS; FOCAL CEREBRAL-ISCHEMIA; STEM-CELLS TRANSPLANTATION; GAMMA-AMINOBUTYRIC-ACID; NITRIC-OXIDE DONOR; DOUBLE-BLIND; BRAIN-INJURY; IN-VITRO;

D O I：

10.3389/fneur.2022.870141

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Stroke is the second most common cause of global death following coronary artery disease. Time is crucial in managing stroke to reduce the rapidly progressing insult of the ischemic penumbra and the serious neurologic deficits that might follow it. Strokes are mainly either hemorrhagic or ischemic, with ischemic being the most common of all types of strokes. Thrombolytic therapy with recombinant tissue plasminogen activator and endovascular thrombectomy are the main types of management of acute ischemic stroke (AIS). In addition, there is a vital need for neuroprotection in the setting of AIS. Neuroprotective agents are important to investigate as they may reduce mortality, lessen disability, and improve quality of life after AIS. In our review, we will discuss the main types of management and the different modalities of neuroprotection, their mechanisms of action, and evidence of their effectiveness after ischemic stroke.

引用

页数：17

共 206 条

[1] Guidelines for the early management of adults with ischemic stroke - A guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the atherosclerotic peripheral vascular disease and quality of care outcomes in research interdisciplinary working groups [J].

Adams, Harold P., Jr. ;

del Zoppo, Gregory ;

Alberts, Mark J. ;

Bhatt, Deepak L. ;

Brass, Lawrence ;

Furlan, Anthony ;

Grubb, Robert L. ;

Higashida, Randall T. ;

Jauch, Edward C. ;

Kidwell, Chelsea ;

Lyden, Patrick D. ;

Morgenstern, Lewis B. ;

Qureshi, Adnan I. ;

Rosenwasser, Robert H. ;

Scott, Phillip A. ;

Wijdicks, Eelco F. M. .

STROKE, 2007, 38 (05) :1655-1711

[2] Evaluation of the intravenous magnesium sulfate effect in clinical improvement of patients with acute ischemic stroke [J].

Afshari, Daryoush ;

Moradian, Nasrin ;

Rezaei, Mansour .

CLINICAL NEUROLOGY AND NEUROSURGERY, 2013, 115 (04) :400-404

[3] Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging [J].

Albers, G. W. ;

Marks, M. P. ;

Kemp, S. ;

Christensen, S. ;

Tsai, J. P. ;

Ortega-Gutierrez, S. ;

McTaggart, R. A. ;

Torbey, M. T. ;

Kim-Tenser, M. ;

Leslie-Mazwi, T. ;

Sarraj, A. ;

Kasner, S. E. ;

Ansari, S. A. ;

Yeatts, S. D. ;

Hamilton, S. ;

Mlynash, M. ;

Heit, J. J. ;

Zaharchuk, G. ;

Kim, S. ;

Carrozzella, J. ;

Palesch, Y. Y. ;

Demchuk, A. M. ;

Bammer, R. ;

Lavori, P. W. ;

Broderick, J. P. ;

Lansberg, M. G. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (08) :708-718

[4] CEREBRAL ARTERIAL SPASM - A CONTROLLED TRIAL OF NIMODIPINE IN PATIENTS WITH SUBARACHNOID HEMORRHAGE [J].

ALLEN, GS ;

AHN, HS ;

PREZIOSI, TJ ;

BATTYE, R ;

BOONE, SC ;

CHOU, SN ;

KELLY, DL ;

WEIR, BK ;

CRABBE, RA ;

LAVIK, PJ ;

ROSENBLOOM, SB ;

DORSEY, FC ;

INGRAM, CR ;

MELLITS, DE ;

BERTSCH, LA ;

BOISVERT, DPJ ;

HUNDLEY, MB ;

JOHNSON, RK ;

STROM, JA ;

TRANSOU, CR .

NEW ENGLAND JOURNAL OF MEDICINE, 1983, 308 (11) :619-624

[5] Excitatory and inhibitory amino acid neurotransmitters in stroke: from neurotoxicity to ischemic tolerance [J].

Amantea, Diana ;

Bagetta, Giacinto .

CURRENT OPINION IN PHARMACOLOGY, 2017, 35 :111-119

[6] Feasibility of an Ambulance-Based Stroke Trial, and Safety of Glyceryl Trinitrate in Ultra-Acute Stroke The Rapid Intervention With Glyceryl Trinitrate in Hypertensive Stroke Trial (RIGHT, ISRCTN66434824) [J].

Ankolekar, Sandeep ;

Fuller, Michael ;

Cross, Ian ;

Renton, Cheryl ;

Cox, Patrick ;

Sprigg, Nikola ;

Siriwardena, A. Niroshan ;

Bath, Philip M. .

STROKE, 2013, 44 (11) :3120-3128

[7]

[Anonymous], 2004, J RES MED SCI

[8] NXY-059, a Failed Stroke Neuroprotectant, Offers No Protection to Stem Cell-Derived Human Neurons [J].

Antonic, Ana ;

Dottori, Mirella ;

Macleod, Malcolm R. ;

Donnan, Geoffrey A. ;

Howells, David W. .

JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2018, 27 (08) :2158-2165

[9] Molecular Pathophysiology of Cerebral Hemorrhage Secondary Brain Injury [J].

Aronowski, Jaroslaw ;

Zhao, Xiurong .

STROKE, 2011, 42 (06) :1781-1786

[10] Stroke and T-cells [J].

Arumugam, TV ;

Granger, DN ;

Mattson, MP .

NEUROMOLECULAR MEDICINE, 2005, 7 (03) :229-242

← 1 2 3 4 5 6 7 8 9 10 →